Tectonic Therapeutic (TECX) Price & Analysis

Compare

629 Followers

TECX Stock Chart & Stats

$19.76

-$0.66(-1.42%)

At close: Jan 08 4:00 PM EST

$19.76

-$0.66(-1.42%)

Day’s Range― - ―

52-Week Range$13.70 - $61.07

Previous CloseN/A

Volume30.18K

Average Volume (3M)365.57K

Market Cap

$364.41M

Enterprise ValueN/A

Total Cash (Recent Filing)$268.44M

Total Debt (Recent Filing)$1.24M

Price to Earnings (P/E)―

Beta1.44

Next Earnings

Mar 19, 2026

EPS Estimate

-1.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.02

Shares Outstanding18,716,280

10 Day Avg. Volume247,027

30 Day Avg. Volume365,572

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)2.78

Price to Sales (P/S)0.00

P/FCF Ratio-6.62

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$86.25

Price Target Upside336.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-4.21

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMerck's decision to progress to a Phase 3 study suggests strong data from its Phase 2 CADENCE trial, which could have a positive influence on Tectonic's TX45.

Funding And Financial StabilityTectonic ends Q3 with $268.4M on the balance sheet, which is expected to fund operations into the fourth quarter of 2028.

Market PotentialRecent positive Phase 1b PH-HFrEF data potentially opens up TX45's total addressable market.

Bears Say

Clinical Trial ChallengesChallenges in the Re-PHIRE trial design could make it difficult to achieve its primary endpoint, influencing TECX negatively.

Drug Development RisksThe failed volenrelaxin trial casts a cloud over relaxin drug development, raising concerns about the entire drug class.

Investor SentimentShort interest is at 33.6% of float, indicating significant bearish sentiment among investors.

Tectonic Therapeutic News

Positive Outlook for Tectonic Therapeutic: Buy Rating Supported by Strategic Focus and Promising Trial Results

LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Tectonic Therapeutic yesterday and set a price...

26d ago

TECX

Promising Outlook for Tectonic Therapeutic: Buy Rating Affirmed Amid Strong Financials and Progress in TX45 Trial

LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Tectonic Therapeutic today and set a price...

1M ago

TECX

Tectonic Therapeutic Reports Q3 2025 Financial Results

Tectonic Therapeutic Inc ( ($TECX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

TECX

Tectonic Therapeutic reports Q3 EPS ($1.02), consensus ($1.05)

“Our team continued to advance our lead asset TX45 with the positive topline data from Part B of...

1M ago

TECX

Tectonic Therapeutic Reports Positive Phase 1b Trial Results

Tectonic Therapeutic ( ($TECX) ) has shared an announcement. On October 29, 2025, Tectonic Therapeutic announced positive topline...

2M ago

TECX

Promising Phase 1b Trial Results and Market Expansion Justify Buy Rating for Tectonic Therapeutic

Tectonic Therapeutic, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Cory Jubinville, PhD...

2M ago

TECX

Tectonic Therapeutic Inc trading resumes

16:35 EDT Tectonic Therapeutic (TECX) Inc trading resumes Published first on TheFly – the ultimate source for real-time,...

2M ago

TECX

Tectonic Therapeutic Inc trading halted, news pending

16:00 EDT Tectonic Therapeutic (TECX) Inc trading halted, news pending Published first on TheFly – the ultimate source...

2M ago

TECX

Tectonic Therapeutic’s Promising Phase 2 Study on TX000045 for Pulmonary Hypertension

Tectonic Therapeutic Inc (($TECX)) announced an update on their ongoing clinical study. Study Overview: Tectonic Therapeutic Inc. is...

2M ago

TECX

3 ‘Strong Buy’ Biotech Stocks Top Analysts Believe Have Over 300% Upside

Wall Street analysts don’t hand out “Strong Buy” ratings lightly. When they do, it usually means they’re convinced...

3M ago

CGEM

TECX

Optimistic Outlook on Tectonic Therapeutic: Strategic Trial Design and Upcoming Catalysts

Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday....

3M ago

TECX

Tectonic Therapeutic initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $80 price target The firm likes...

3M ago

TECX

Confidence in Tectonic Therapeutic’s Strategic Approach Amid Eli Lilly’s Trial Setback

Danielle Brill, an analyst from Truist Financial, maintained the Buy rating on Tectonic Therapeutic. The associated price target...

3M ago

TECX

Tectonic pullback on Eli Lilly relaxin data ‘overdone,’ says Truist

Truist analyst Danielle Brill notes that shares of Tectonic Therapeutic (TECX) are off by greater than 30% following...

3M ago

LLY

TECX

TECX FAQ

What was Tectonic Therapeutic’s price range in the past 12 months?

Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.

What is Tectonic Therapeutic’s market cap?

Tectonic Therapeutic’s market cap is $364.41M.

When is Tectonic Therapeutic’s upcoming earnings report date?

Tectonic Therapeutic’s upcoming earnings report date is Mar 19, 2026 which is in 95 days.

How were Tectonic Therapeutic’s earnings last quarter?

Tectonic Therapeutic released its earnings results on Nov 06, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.036.

Is Tectonic Therapeutic overvalued?

According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tectonic Therapeutic pay dividends?

Tectonic Therapeutic does not currently pay dividends.

What is Tectonic Therapeutic’s EPS estimate?

Tectonic Therapeutic’s EPS estimate is -1.13.

How many shares outstanding does Tectonic Therapeutic have?

Tectonic Therapeutic has 18,716,280 shares outstanding.

What happened to Tectonic Therapeutic’s price movement after its last earnings report?

Tectonic Therapeutic reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 1.738%.

Which hedge fund is a major shareholder of Tectonic Therapeutic?

Currently, no hedge funds are holding shares in TECX

Tectonic Therapeutic Stock Smart Score

Neutral

Fundamentals

Return on Equity

-32.21%

Trailing 12-Months

Asset Growth

64.18%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tectonic Therapeutic

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.

Tectonic Therapeutic (TECX) Earnings & Revenues

Historic Earnings Reports

TECX Stock 12 Month Forecast

Average Price Target

$86.25

▲(336.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","36":"$36","58":"$58","80":"$80","102":"$102"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$86.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$76.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,36,58,80,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.25,24.615384615384613,30.98076923076923,37.34615384615385,43.71153846153846,50.07692307692307,56.44230769230769,62.80769230769231,69.17307692307692,75.53846153846153,81.90384615384615,88.26923076923076,94.63461538461539,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.25,23.48076923076923,28.71153846153846,33.94230769230769,39.17307692307692,44.40384615384615,49.63461538461539,54.86538461538461,60.09615384615385,65.32692307692308,70.5576923076923,75.78846153846155,81.01923076923077,{"y":86.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.25,22.692307692307693,27.134615384615387,31.576923076923077,36.019230769230774,40.46153846153847,44.90384615384615,49.34615384615385,53.78846153846154,58.23076923076923,62.67307692307693,67.11538461538461,71.5576923076923,{"y":76,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.33,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >